Drugs / HLX53
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05394168 | Dec 2022 → Dec 2024 | — | Shanghai Henlius Biotech | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06349980 | Aug 2024 → Feb 2027 expected | hepatocellular carcinoma | Shanghai Henlius Biotech | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HLX53 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06349980 ↗ |
| Action | Inhibit | “anti-TIGIT Fc fusion protein” NCT05394168 ↗ |
| Modality | Protein / enzyme biologic | “HLX53 (an anti-TIGIT Fc fusion protein)” NCT05394168 ↗ |
| Route | Intravenous | “administered by intravenous infusion” NCT05394168 ↗ |
| Target | TIGIT | “HLX53 (an Anti-TIGIT Fc Fusion Protein)” NCT06349980 ↗ |